Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... Emerging treatment concepts include novel combination of well-know agents such as rituximab and chlorambucil, fludarabine, cyclophosphamide and alemtuzumab, FCR with mitoxantrone ...
2009 NOV 23 ... the therapeutic response rate of B-cell non-Hodgkin's lymphoma (B-NHL) patients to rituximab treatment. This was based on a well defined, retrospective analysis of patient samples ...
2009 NOV 16 ... (NHL) whose disease had progressed during or within six months of treatment with rituximab. Results of this study, which supported the FDA approval of TREANDA in this patient ...
2009 NOV 16 ... three times per week." "Dose escalation to 110 mg or the addition of rituximab was permitted in patients without a response after two or more cycles. MGCD0103 ...
2009 NOV 16 ... with SIVagm. sab. Four AGMs were infused with 50 mg/kg of body weight anti-CD20 (rituximab; a gift from Genentech) every 21 days, starting from day -7 postinfection up to 184 ...
2009 NOV 23 ... gammopathy of undetermined significance. Newer studies have shown promising results with rituximab, a monoclonal antibody which targets the B cell surface antigen CD20 and results in a ...
2009 NOV 16 ... risk factors." "Monitoring of EBV DNA load and early administration of rituximab in patients with high EBV loads is recommended for high-risk patients. Patients at high ...
2009 NOV 23 ... required at least one ''second-line'' treatment, including splenectomy(n = 19) and rituximab (n = 11). At time of analysis, after a mean follow-up of 4.8 years, only 22 patients ...
2009 NOV 9 ... interleukin-1 receptor antagonist, IL1-RA, infliximab, leflunomide, methotrexate, rituximab, and sulfasalazine/sulphasalazine). Reference lists of the retrieved publications were ...
2009 NOV 23 ... doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index ...
2009 NOV 9 ... 80%-90% are routinely achieved, and survival is now approaching 80% with the addition of rituximab to these intensive regimens. Prophylactic cranial irradiation and prolonged maintenance ...
2009 NOV 29 ... improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly ...
2009 NOV 23 ... than 60% of patients with diffuse large B-cell lymphoma (DLBCL) will be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, the ...
2009 NOV 2 ... Ib clinical trials at ASH, including dacetuzumab in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for relapsed and refractory diffuse large B-cell ...
2009 NOV 9 ... publish new data in the report 'Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.' "Rituximab ...
2009 NOV 23 ... Scientists discuss in 'Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk ...
2009 NOV 16 ... results from the international phase III study PRIMA1, which show that MabThera (rituximab) maintenance therapy can significantly increase the time until the disease progresses in ...
